No English Funding For Lymphoma Drugs Ledaga and Poteligeo
Issues With Clinical Trial Design Among Issues Of Concern To HTA Body NICE
Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.
You may also be interested in...
Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include six new products, including bluebird bio's Skysona, the first gene therapy approved in the EU to treat early cerebral adrenoleukodystrophy.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.